Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kobe-Based M's Science To Accelerate Cerebral Infarction Clinical Drug Trials

This article was originally published in PharmAsia News

Executive Summary

Kobe-based clinical stage drug discovery and development venture company, M's Science, announced the allocation of new shares to a third party May 26 in an effort to speed up clinical trials for SA4503. Developed by the company, SA4503 is a drug agent with potential applications for treating cerebral infarction and depression, and currently it is in Phase II trials in Europe. The ¥940 million investment infusion comes from 16 venture capital companies, including Japan Asia Investment Corp, Yasuda Enterprise Development and First Track Initiative. The funds will be used to speed up the trials. (Click here for more - Japanese language

You may also be interested in...



Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'

Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

UsernamePublicRestriction

Register

SC068602

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel